Brokerages Set Twist Bioscience Co. (NASDAQ:TWST) PT at $51.90

Twist Bioscience Co. (NASDAQ:TWST) has earned an average recommendation of “Moderate Buy” from the ten brokerages that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $51.90.

Several analysts recently weighed in on TWST shares. Evercore ISI upped their price target on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Scotiabank upped their target price on shares of Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, November 19th. Barclays cut their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a report on Tuesday, November 19th. Leerink Partners increased their price objective on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. Finally, Wolfe Research assumed coverage on Twist Bioscience in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective for the company.

Twist Bioscience Trading Down 3.4 %

TWST opened at $43.60 on Wednesday. The company has a market cap of $2.59 billion, a price-to-earnings ratio of -12.11 and a beta of 1.85. The stock has a fifty day simple moving average of $46.35 and a two-hundred day simple moving average of $46.46. Twist Bioscience has a 12-month low of $27.41 and a 12-month high of $60.90.

Insider Buying and Selling

In related news, CFO Adam Laponis sold 4,160 shares of the business’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $44.60, for a total transaction of $185,536.00. Following the transaction, the chief financial officer now directly owns 89,237 shares in the company, valued at $3,979,970.20. The trade was a 4.45 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CAO Robert F. Werner sold 1,448 shares of the firm’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $44.60, for a total value of $64,580.80. Following the completion of the transaction, the chief accounting officer now owns 45,620 shares of the company’s stock, valued at $2,034,652. This trade represents a 3.08 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 83,754 shares of company stock valued at $3,869,144. Insiders own 3.92% of the company’s stock.

Institutional Investors Weigh In On Twist Bioscience

Institutional investors have recently modified their holdings of the business. State Street Corp grew its position in shares of Twist Bioscience by 19.9% in the third quarter. State Street Corp now owns 3,167,353 shares of the company’s stock valued at $143,101,000 after purchasing an additional 526,028 shares during the period. Geode Capital Management LLC lifted its stake in Twist Bioscience by 1.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company’s stock valued at $61,807,000 after buying an additional 26,145 shares in the last quarter. Thrivent Financial for Lutherans acquired a new stake in Twist Bioscience in the 3rd quarter worth about $43,992,000. Wellington Management Group LLP increased its stake in Twist Bioscience by 188.5% during the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after buying an additional 521,272 shares in the last quarter. Finally, Fred Alger Management LLC raised its holdings in shares of Twist Bioscience by 17.1% during the third quarter. Fred Alger Management LLC now owns 767,149 shares of the company’s stock valued at $34,660,000 after acquiring an additional 112,272 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.